Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis

Código QR

Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis

Guardado en:

Detalles Bibliográficos
Autores principales:	Christopher Oldmeadow, Angela Smith, Madeleine Hinwood, Danielle Lang, Samuel Lees, Mathew Dicker, Jie En Ku, Varun Chaganti, Matthew Mew-Sum, Nick Wang, Wooi Lynn Goon, Marc Bevan
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/5ae081a7c0384ea8894d5580efdd82ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
por: Fabricio Gonz&aacute;lez-Andrade, et al.
Publicado: (2010)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Julie A Murphy, et al.
Publicado: (2010)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Karl E. Carlström, et al.
Publicado: (2019)

Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.
por: Henrik Lund, et al.
Publicado: (2013)

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.
por: Mark Lyksborg, et al.
Publicado: (2014)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
por: Anne Waschbisch, et al.
Publicado: (2011)

Synchronization within, and interactions between, the default mode and dorsal attention networks in relapsing-remitting multiple sclerosis
por: Huang M, et al.
Publicado: (2018)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
por: Ratthaporn Boonsuth, et al.
Publicado: (2021)

A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis
por: Eoin F. McKinney, et al.
Publicado: (2021)

Promising Effects of Vitex Agnus-Castus on Quality of Life and Sexual Function in Premenopausal Relapsing Remitting Multiple Sclerosis Patients
por: Sara Rahgooy, et al.
Publicado: (2020)

Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
por: Sylwia Pietrasik, et al.
Publicado: (2021)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran JQ, et al.
Publicado: (2016)

Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study
por: Liu H, et al.
Publicado: (2016)

Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls.
por: Andreas Keller, et al.
Publicado: (2009)

Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis
por: Georgios Efthymiou, et al.
Publicado: (2017)

Altered intra- and interregional synchronization in relapsing–remitting multiple sclerosis: a resting-state fMRI study
por: Wu L, et al.
Publicado: (2016)

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing&ndash;remitting multiple sclerosis?
por: Mezei Z, et al.
Publicado: (2012)

Disconnection of the hippocampus and amygdala associated with lesion load in relapsing–remitting multiple sclerosis: a structural and functional connectivity study
por: Zhou F, et al.
Publicado: (2015)

Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey
por: Gross HJ, et al.
Publicado: (2017)

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Aliza Bitton Ben-Zacharia, et al.
Publicado: (2021)

Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report
por: De Pasquale C, et al.
Publicado: (2014)

CELLULAR IMMUNITY PARAMETERS IN PATIENTS WITH REMITTING MULTIPLE SCLEROSIS
por: I. P. Ivanova, et al.
Publicado: (2021)

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
por: Francesco Patti, et al.
Publicado: (2013)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Richard A Rudick, et al.
Publicado: (2008)

Remitting long-standing major depression in a multiple sclerosis patient with several concurrent conditions
por: Sachinvala ND, et al.
Publicado: (2018)

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
por: Kerstin Hellwig, et al.
Publicado: (2021)

Activities report of the working group on migration and trends in remitances
Publicado: (2014)

Vitamin D and neurocognitive function
por: Schlögl M, et al.
Publicado: (2014)

Neurocognitive endophenotypes: an update on the Field.
por: Jorge Mauricio Cuartas Arias, et al.
Publicado: (2016)

Neurocognitive domains and neuropathological changes in experimental infection with Trypanosoma brucei brucei in Wistar rats
por: Olamide Elizabeth Adebiyi, et al.
Publicado: (2021)

Pathways of the brain: The neurocognitive basis of language
por: Silva,Omer
Publicado: (2000)

Narcolepsy Type 1: A Remitting Disease? An Unusual Case Report
por: Vellieux G, et al.
Publicado: (2021)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey D, et al.
Publicado: (2015)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan S
Publicado: (2016)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Slobodan M Jankovic
Publicado: (2010)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Damiano Paolicelli, et al.
Publicado: (2009)

Decision-making ability of professional managers based on neurocognitive
por: Liang Guo, et al.
Publicado: (2019)

Neurocognitive development of novelty and error monitoring in children and adolescents
por: Kathleen Kang, et al.
Publicado: (2021)

The Role of Perioperative Sleep Disturbance in Postoperative Neurocognitive Disorders
por: Wang X, et al.
Publicado: (2021)